Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Roivant Sciences Ltd. before investing.

In this article, we go over a few key elements for understanding Roivant Sciences Ltd.’s stock price such as:

• Roivant Sciences Ltd.’s current stock price and volume
• Why Roivant Sciences Ltd.’s stock price changed recently
• Upgrades and downgrades for ROIV from analysts
• ROIV’s stock price momentum as measured by its relative strength

About Roivant Sciences Ltd. (ROIV)

Before we jump into Roivant Sciences Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Want to learn more about Roivant Sciences Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Roivant Sciences Ltd..

Roivant Sciences Ltd.’s Stock Price as of Market Close

As of February 06, 2026, 3:59 PM, CST, Roivant Sciences Ltd.’s stock price was $25.820.

Roivant Sciences Ltd. is up 22.14% from its previous closing price of $21.140.

During the last market session, Roivant Sciences Ltd.’s stock traded between $23.973 and $25.950. Currently, there are approximately 696.86 million shares outstanding for Roivant Sciences Ltd..

Roivant Sciences Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Roivant Sciences Ltd. Stock Price History

Roivant Sciences Ltd.’s (ROIV) price is currently up 19.43% so far this month.

During the month of February, Roivant Sciences Ltd.’s stock price has reached a high of $25.950 and a low of $20.980.

Over the last year, Roivant Sciences Ltd. has hit prices as high as $25.950 and as low as $8.730. Year to date, Roivant Sciences Ltd.’s stock is up 18.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Roivant Sciences Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 06, 2026, there was 1 analyst who downgraded Roivant Sciences Ltd.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Roivant Sciences Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Roivant Sciences Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Roivant Sciences Ltd. (ROIV) by visiting AAII Stock Evaluator.

Relative Price Strength of Roivant Sciences Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 06, 2026, Roivant Sciences Ltd. has a weighted four-quarter relative price strength of 23.11%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Roivant Sciences Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Roivant Sciences Ltd. Stock Price: Bottom Line

As of February 6, 2026, Roivant Sciences Ltd.’s stock price is $25.820, which is up 22.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Roivant Sciences Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.